BiotechTube

GEMZAR + ALIMTA

Phase 3Completed
3 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Neoplasms

Conditions

Pancreatic Neoplasms, Metastases, Neoplasm

Trial Timeline

— → —

NCT ID
NCT00035035

About GEMZAR + ALIMTA

GEMZAR + ALIMTA is a phase 3 stage product being developed by Eli Lilly for Pancreatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00035035. Target conditions include Pancreatic Neoplasms, Metastases, Neoplasm.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Neoplasms were approved

Approved (9) Terminated (5) Active (10)
✅DalteparinEisaiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PlaceboAbbVieApproved
✅Pancrelipase CapsulesAbbVieApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00035035Phase 3Completed

Competing Products

20 competing products in Pancreatic Neoplasms

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
pemetrexedEli LillyPhase 2
35
mFOLFIRINOX + RamucirumabEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
enzastaurin + gemcitabineEli LillyPhase 2
35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
29
RamucirumabEli LillyPhase 1/2
32
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
35
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
29
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
29
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
35
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
40
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
29